CTI BioPharma Corp. (NASDAQ:CTIC) has analysts on the Bullish side this week.

July 14, 2018 - By Harriett Tippett

CTI BioPharma Corp. (NASDAQ:CTIC) Logo

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Coverage

Among 3 analysts covering CTI BioPharma (NASDAQ:CTIC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CTI BioPharma has $8 highest and $5 lowest target. $6.50’s average target is 57.38% above currents $4.13 stock price. CTI BioPharma had 3 analyst reports since February 23, 2018 according to SRatingsIntel. The stock of CTI BioPharma Corp. (NASDAQ:CTIC) earned “Buy” rating by Needham on Monday, March 26. Below is a list of CTI BioPharma Corp. (NASDAQ:CTIC) latest ratings and price target changes.

26/03/2018 Broker: Needham Rating: Buy Initiate
07/03/2018 Broker: JMP Securities Rating: Outperform New Target: $8 Initiates Coverage On
23/02/2018 Broker: Oppenheimer Rating: Outperform New Target: $5 Initiates Coverage On

The stock decreased 3.73% or $0.16 during the last trading session, reaching $4.13. About 443,581 shares traded or 5.65% up from the average. CTI BioPharma Corp. (NASDAQ:CTIC) has risen 15.83% since July 14, 2017 and is uptrending. It has outperformed by 3.26% the S&P500.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company has market cap of $239.46 million. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. It currently has negative earnings. The firm is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis.

More notable recent CTI BioPharma Corp. (NASDAQ:CTIC) news were published by: Streetinsider.com which released: “Pre-Open Movers 07/09: (MBVX) (HELE) (GRPN) Higher; (CTIC) (PETS) (PG) Lower (more…)” on July 09, 2018, also Seekingalpha.com with their article: “CTI Bio’s Pixuvri flunks late-stage NHL study; shares halted” published on July 09, 2018, Streetinsider.com published: “CTI BioPharma (CTIC) Announces Continuation without Modification of PAC203 Phase 2 Study of Pacritinib Following …” on July 02, 2018. More interesting news about CTI BioPharma Corp. (NASDAQ:CTIC) were released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Dow Rises 1.25%; Staffing 360 Solutions Shares Surge” published on July 09, 2018 as well as Streetinsider.com‘s news article titled: “After-Hours Stock Movers 07/09: (OCX) (XLRN) (HEAR) Higher; (AQXP) (SPRO) (WHD) Lower (more…)” with publication date: July 09, 2018.

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: